Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-κB system in high-fat-fed rabbits

Journal of Pineal Research

Volumn 55, Issue 4, 2013, Pages 388-398

  Hu, Ze Ping ^a   Fang, Xiao Ling ^a   Fang, Nan ^a   Wang, Xiao Bian ^a   Qian, Hai Yan ^b   Cao, Zhong ^a   Cheng, Yuan ^a   Wang, Bang Ning ^a   Wang, Yuan ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

atherosclerosis; inflammation; melatonin; TLR4 NF B system; vascular endothelial function

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELATONIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL RABBIT; HISTOLOGY; IMMUNOBLOTTING; INFLAMMATION; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; NONHUMAN; PROTEIN EXPRESSION; VASCULAR ENDOTHELIAL DYSFUNCTION; VASCULARIZATION;

ATHEROSCLEROSIS; INFLAMMATION; MELATONIN; TLR4/NF-ΚB SYSTEM; VASCULAR ENDOTHELIAL FUNCTION;

ANIMALS; ATHEROSCLEROSIS; DIET, HIGH-FAT; INFLAMMATION; MALE; MELATONIN; NF-KAPPA B; RABBITS; TOLL-LIKE RECEPTOR 4;

EID: 84885628446     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12085     Document Type: Article

References (70)

1. Frohlich J, Al-Sarraf A,. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol 2013; 22: 16-18.
2. Briasoulis A, Tousoulis D, Androulakis ES, et al. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Discov 2012; 7: 21-32.
3. Tabas I, Glass CK,. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339: 166-172.
4. Baruch A, van Bruggen N, Kim JB, et al. Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes. Curr Atheroscler Rep 2013; 15: 327.
5. Ishida BY, Blanche PJ, Nichols AV, et al. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 1991; 32: 559-568.
6. Nishina PM, Wang J, Toyofuku W, et al. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 1993; 28: 599-605.
7. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-10684.
8. Blich M, Golan A, Arvatz G, et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 2013; 33: e56-e65.
9. Ishikawa Y, Satoh M, Itoh T, et al. Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin Sci(Lond) 2008; 115: 133-140.
10. Hodgkinson CP, Ye S,. Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenet Genomics 2008; 18: 803-813.
11. Shen DZ, Xin SL, Chen C, et al. Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits. Asian Pac J Trop Med 2013; 6: 493-496.
12. Yue ZH, He XQ, Chang XR, et al. The effect of herb-partition moxibustion on Toll-like receptor 4 in rabbit aorta during atherosclerosis. J Acupunct Meridian Stud 2012; 5: 72-79.
13. Soraya H, Farajnia S, Khani S, et al. Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected? Int Immunopharmacol 2012; 14: 785-791.
14. Subramanian M, Thorp E, Hansson GK, et al. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. Clin Invest 2013; 123: 179-188.
15. Tapp LD, Shantsila E, Wrigley BJ, et al. TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med 2013; 273: 294-305.
16. Wang E, Feng Y, Zhang M, et al. Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms. Anesthesiology 2011; 114: 603-613.
17. Lerner AB, Case JD, Takahashi Y,. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem 1960; 235: 1992-1997.
18. Skinner DC, Malpaux B,. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 1999; 140: 4399-4405.
19. Yu HS, Yee RW, Howes KA, et al. Diurnal rhythms of immunoreactive melatonin in the aqueous humor and serum of male pigmented rabbits. Neurosci Lett 1990; 116: 309-314.
20. Tan D, Manchester LC, Reiter RJ, et al. High physiological levels of melatonin in the bile of mammals. Life Sci 1999; 65: 2523-2529.
21. Nakamura Y, Tamura H, Takayama H, et al. Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production. Fertil Steril 2003; 80: 1012-1016.
22. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
23. Lax P, Otalora BB, Esquiva G, et al. Circadian dysfunction in P23H rhodopsin transgenic rats: effects of exogenous melatonin. J Pineal Res 2011; 50: 183-191.
24. Lyseng-Williamson KA,. Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years. Drugs Aging 2012; 29: 911-923.
25. Markus RP, Cecon E, Pires-Lapa MA,. Immune-Pineal Axis: Nuclear Factor κB (NF-kB) mediates the shift in the melatonin source from Pinealocytes to Immune Competent Cells. Int J Mol Sci 2013; 14: 10979-10997.
26. Li HL, Kang YM, Yu L, et al. Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. Clin Exp Pharmacol Physiol 2009; 36: 436-440.
27. Simko F, Paulis L,. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42: 319-322.
28. Scheer FA, van Montfrans GA, van Someren EJ, et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43: 192-197.
29. Fischer TW, Kleszczynski K, Hardkop LH, et al. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2′-deoxyguanosine) in ex vivo human skin. J Pineal Res 2013; 54: 303-312.
30. Mauriz JL, Molpeceres V, Garcia-Mediavilla MV, et al. Melatonin prevents oxidative stress and changes in antioxidant enzyme expression and activity in the liver of aging rats. J Pineal Res 2007; 42: 222-230.
31. Teixeira A, Morfim MP, de Cordova CA, et al. Melatonin protects against pro-oxidant enzymes and reduces lipid peroxidation in distinct membranes induced by the hydroxyl and ascorbyl radicals and by peroxynitrite. J Pineal Res 2003; 35: 262-268.
32. Rezzani R, Porteri E, de Ciuceis C, et al. Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension 2010; 55: 1373-1380.
33. Rodella LF, Favero G, Foglio E, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Front Biosci (Elite Ed) 2013; 5: 119-129.
34. Xia MZ, Liang YL, Wang H, et al. Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells. J Pineal Res 2012; 53: 325-334.
35. Tamura EK, Cecon E, Monteiro AW, et al. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J Pineal Res 2009; 46: 268-274.
36. Gilad E, Wong HR, Zingarelli B, et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 1998; 12: 685-693.
37. Mohan N, Sadeghi K, Reiter RJ, et al. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995; 37: 1063-1070.
38. Chuang JI, Mohan N, Meltz ML, et al. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int 1996; 20: 687-692.
39. Cuesta S, Kireev R, Forman K, et al. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Exp Gerontol 2010; 45: 950-956.
40. Carrillo-Vico A, Lardone PJ, Naji L, et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 2005; 39: 400-408.
41. Mauriz JL, Collado PS, Veneroso C, et al. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
42. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 2008; 44: 65-69.
43. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. Thromb Res 2007; 120: 361-366.
44. Dominguez-Rodriguez A, Garcia-Gonzalez M, Abreu-Gonzalez P, et al. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97: 10-12.
45. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia M, et al. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004; 26: 89-93.
46. Tailleux A, Torpier G, Bonnefont-Rousselot D, et al. Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem Biophys Res Commun 2002; 293: 1114-1123.
47. Kang JW, Koh EJ, Lee SM,. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res 2011; 50: 403-411.
48. Chen YX, Wang XQ, Fu Y, et al. Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin. Int J Cardiol 2011; 146: 140-144.
49. Drolet MC, Plante E, Battistini B, et al. Early endothelial dysfunction in cholesterol-fed rabbits: a non-invasive in vivo ultrasound study. Cardiovasc Ultrasound 2004; 2: 10.
50. Zhou B, Pan Y, Hu Z, et al. All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation. J Biomed Biotechnol 2012; 2012: 259693.
51. Tripepi G,. Mattace, RASO F, SIJBRANDS E, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011; 6: 1714-1721.
52. Yamazaki T, Nohara R, Daida H, et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. Int Heart J 2013; 54: 33-39.
53. Hoyos M, Guerrero JM, Perez-Cano R, et al. Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats. J Pineal Res 2000; 28: 150-155.
54. Hussein MR, Ahmed OG, Hassan AF, et al. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol 2007; 88: 19-29.
55. Dauchy RT, Blask DE, Sauer LA, et al. Physiologic melatonin concentration, omega-3 fatty acids, and conjugated linoleic acid inhibit fatty acid transport in rodent hind limb skeletal muscle in vivo. Comp Med 2003; 53: 186-190.
56. Vaughan MK, Powanda MC, Brainard GC, et al. Effects of blinding or afternoon melatonin injections on plasma cholesterol, triglycerides, glucose, TSH and thyroid hormone levels in male and female Syrian hamsters. Prog Clin Biol Res 1982; 92: 177-186.
57. Mudau M, Genis A, Lochner A, et al. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr 2012; 23: 222-231.
58. Zhu HQ, Cheng XW, Xiao LL, et al. Melatonin prevents oxidized low-density lipoprotein-induced increase of myosin light chain kinase activation and expression in HUVEC through ERK/MAPK signal transduction. J Pineal Res 2008; 45: 328-334.
59. Reyes-Toso CF, Obaya-Naredo D, Ricci CR, et al. Effect of melatonin on vascular responses in aortic rings of aging rats. Exp Gerontol 2007; 42: 337-342.
60. Reyes-Toso CF, Linares LM, Ricci CR, et al. Effect of melatonin on vascular reactivity in pancreatectomized rats. Life Sci 2004; 74: 3085-3092.
61. Sartori C, Dessen P, Mathieu C, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 2009; 150: 5311-5317.
62. Bertuglia S, Reiter RJ,. Melatonin reduces ventricular arrhythmias and preserves capillary perfusion during ischemia-reperfusion events in cardiomyopathic hamsters. J Pineal Res 2007; 42: 55-63.
63. Rodella LF, Favero G, Rossini C, et al. Endothelin-1 as a potential marker of melatonin's therapeutic effects in smoking-induced vasculopathy. Life Sci 2010; 87: 558-564.
64. Li SN, Wang X, Zeng QT, et al. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels 2009; 24: 446-453.
65. Erickson B, Sperber K, Frishman WH,. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev 2008; 16: 273-279.
66. Frantz S, Ertl G, Bauersachs J,. Toll-like receptor signaling in the ischemic heart. Front Biosci 2008; 13: 5772-5779.
67. Edfeldt K, Swedenborg J, Hansson GK, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 002; 105: 1158-1161.
68. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-3108.
69. Su X, Ao L, Shi Y, et al. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J Biol Chem 2011; 286: 12213-12220.
70. Tomofuji T, Ekuni D, Azuma T, et al. Involvement of toll-like receptor 2 and 4 in association between dyslipidemia and osteoclast differentiation in apolipoprotein E deficient rat periodontium. Lipids Health Dis 2013; 12: 1.